Revance Therapeutics, Inc. (NASDAQ:RVNC – Get Rating) saw some unusual options trading activity on Wednesday. Stock investors bought 18,077 call options on the stock. This represents an increase of 472% compared to the typical daily volume of 3,161 call options.

Revance Therapeutics Stock Down 3.4 %

Shares of RVNC traded down $0.64 during mid-day trading on Wednesday, hitting $18.07. The company’s stock had a trading volume of 91,727 shares, compared to its average volume of 1,047,991. The company’s 50-day moving average is $21.89 and its 200-day moving average is $20.73. Revance Therapeutics has a 52-week low of $11.27 and a 52-week high of $30.95. The firm has a market capitalization of $1.49 billion, a price-to-earnings ratio of -4.66 and a beta of 0.52. The company has a current ratio of 5.56, a quick ratio of 5.33 and a debt-to-equity ratio of 2.60.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of RVNC. Advisor Group Holdings Inc. raised its stake in shares of Revance Therapeutics by 60.6% during the 1st quarter. Advisor Group Holdings Inc. now owns 2,838 shares of the biopharmaceutical company’s stock worth $56,000 after acquiring an additional 1,071 shares in the last quarter. Principal Financial Group Inc. raised its stake in shares of Revance Therapeutics by 7.6% during the 1st quarter. Principal Financial Group Inc. now owns 12,850 shares of the biopharmaceutical company’s stock worth $251,000 after acquiring an additional 913 shares in the last quarter. Citigroup Inc. raised its stake in shares of Revance Therapeutics by 114.2% during the 1st quarter. Citigroup Inc. now owns 12,451 shares of the biopharmaceutical company’s stock worth $243,000 after acquiring an additional 100,141 shares in the last quarter. MetLife Investment Management LLC raised its stake in shares of Revance Therapeutics by 53.8% during the 1st quarter. MetLife Investment Management LLC now owns 39,127 shares of the biopharmaceutical company’s stock worth $763,000 after acquiring an additional 13,694 shares in the last quarter. Finally, Panagora Asset Management Inc. raised its stake in shares of Revance Therapeutics by 358.8% during the 1st quarter. Panagora Asset Management Inc. now owns 49,123 shares of the biopharmaceutical company’s stock worth $958,000 after acquiring an additional 38,416 shares in the last quarter. Institutional investors own 82.68% of the company’s stock.

Analysts Set New Price Targets

Several research firms have issued reports on RVNC. Cowen boosted their price objective on shares of Revance Therapeutics from $55.00 to $65.00 in a research report on Thursday, September 8th. Morgan Stanley lowered their price objective on shares of Revance Therapeutics from $27.00 to $25.00 and set an “equal weight” rating for the company in a research report on Wednesday, November 9th. Barclays boosted their price objective on shares of Revance Therapeutics from $35.00 to $37.00 and gave the company an “overweight” rating in a research report on Wednesday, November 16th. Guggenheim boosted their price objective on shares of Revance Therapeutics to $36.00 in a research report on Tuesday, November 15th. Finally, Cowen boosted their price objective on shares of Revance Therapeutics from $55.00 to $65.00 in a research report on Thursday, September 8th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $37.90.

Revance Therapeutics Company Profile

(Get Rating)

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials for the treatment of glabellar (frown) lines and cervical dystonia; is in phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.

Featured Articles

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Before you consider Revance Therapeutics, you’ll want to hear this.

MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Revance Therapeutics wasn’t on the list.

While Revance Therapeutics currently has a “Moderate Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here